Progress in understanding the mechanisms of resistance to BCL-2 inhibitors

Progress in understanding the mechanisms of resistance to BCL-2 inhibitors

Abstract Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial apoptotic pathway. Venetoclax is especially used to treat haematological malignancies. However, with the recent expans...

Full description

Bibliographic Details
Main Authors: Yilan Xu, Haige Ye
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Experimental Hematology & Oncology
Subjects:
Venetoclax
Resistance
BCL-2
Gene mutations
OXPHOS
Online Access:https://doi.org/10.1186/s40164-022-00283-0

Internet

https://doi.org/10.1186/s40164-022-00283-0

Similar Items